# A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers

> **NCT06870487** · PHASE1 · TERMINATED · sponsor: **Pfizer** · enrollment: 6 (actual)

## Conditions studied

- Peripheral T Cell Lymphoma
- Diffuse Large B-cell Lymphoma
- Classical Hodgkin Lymphoma
- Head and Neck Squamous Cell Carcinoma
- Melanoma
- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** PF-08046032
- **DRUG:** Sasanlimab

## Key facts

- **NCT ID:** NCT06870487
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2025-05-08
- **Primary completion:** 2026-04-23
- **Final completion:** 2026-04-23
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** The trial was terminated for strategic business reasons; the decision was not based on any safety and/or efficacy concerns
- **Last updated:** 2026-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06870487

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06870487, "A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers". Retrieved via AI Analytics 2026-09-21 from https://api.ai-analytics.org/clinical/NCT06870487. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*